Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD.
Wykoff, Charles C
Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. [electronic resource] - Ophthalmology Sep 2013 - 1945-6.e1 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1549-4713
10.1016/j.ophtha.2013.06.030 doi
Angiogenesis Inhibitors--administration & dosage
Antibodies, Monoclonal, Humanized--administration & dosage
Drug Resistance
Female
Humans
Intravitreal Injections
Male
Ranibizumab
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity--physiology
Wet Macular Degeneration--diagnosis
Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. [electronic resource] - Ophthalmology Sep 2013 - 1945-6.e1 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1549-4713
10.1016/j.ophtha.2013.06.030 doi
Angiogenesis Inhibitors--administration & dosage
Antibodies, Monoclonal, Humanized--administration & dosage
Drug Resistance
Female
Humans
Intravitreal Injections
Male
Ranibizumab
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity--physiology
Wet Macular Degeneration--diagnosis